• Japanese
  • Korean
  • Chinese
Cover Image

Medical Imaging Markets: Contrast Agents

Today's capabilities in clinical diagnostic radiology have been made possible by advances not only in diagnostic systems, but also by the contrast media and radiopharmaceuticals that make it possible to see, in great detail, the body's internal structures, organs and tissue that would nototherwise be clearly seen. Although bones are readily apparent on radiographic images, other organs and tissues are not. These imaging agents may be usedduring a medical imaging procedure to highlight specific parts of the body andmake them easier to visualize. The application and versatility of medical imaging modalities are continuing to grow in significance as the population ages and healthcare costs rise. Examinations that can facilitate earlier disease diagnosis and the most appropriate treatment are in order. This bodes well for contrast media markets.

Generally, the market for contrast agents and radiopharmaceuticals is expected to sustain decent growth in the next fewyears, with much of that growth coming from the MRI, ultrasound and nuclear medicine modalities. While equipment manufacturers may have experienced a slumpin sales due to the recent recession, there is still a need for these agents,as well as for radiopharmaceuticals, to help image, track and diagnose disease, especially in the elderly. Even though hospitals and clinics may have slowed their equipment purchases because of the need to contain costs, procedures run on installed systems still require the use of contrast agents and radiopharmaceuticals.

This comprehensive study of the world market for contrast agents builds on the previous modality-focused reports of Kalorama's medical imaging market reports.

Coverage includes:

  • World and regional revenue forecasts for contrast agents and radiopharmaceuticals by modality through 2016. (X-Ray, CT, Ultrasound, MRI, PET, SPECT)
  • Market share of the major contrast agent supplers
  • Procedure volumes by modality and region
  • Estimates of the portion of procedures in each modality using contrast enhancement
  • Contrast-enhancement products in development

The report also discusses technical developments and emerging application trends such as therapeutic monitoring, whole body screening, and guided therapeutic interventions, and how contrast agents are helping to expand imaging's role in basic research and drug discovery/development. Specific advances in contrast agent-enabled diagnostics for mammography, Alzheimer's, and other indications are also reviewed.

The report concludes with profiles of top suppliers and developers including:

  • Acusphere Inc.
  • Alseres Pharmaceuticals Inc.
  • Amag Pharmaceuticals Inc.
  • Aposense Ltd.
  • Avid Radiopharmaceuticals Inc.
  • Bayer Schering Pharma
  • Bracco SpA
  • Cell Point
  • Covidien Ltd.
  • Daiichi Pharmaceutical Co. Ltd.
  • Dendritic NanoTechnologies Inc.
  • Draximage
  • Endocyte Inc.
  • Eusa Pharma
  • GE Healthcare
  • Guerbet Group
  • Hovione FarmaCiencia SA
  • Imcor Pharmaceutical Co.
  • Immunomedics Inc.
  • Insight Agents GmbH
  • King Pharmaceuticals Inc.
  • Luna nanoWorks
  • Macrocyclics
  • MDS Nordion
  • NanoScan Imaging
  • Palatin Technologies Inc.
  • Pharmacyclics
  • Point Biomedical Corp.
  • Starpharma Holdings Ltd.
  • VisEn Medical Inc.

Table of Contents

CHAPTER ONE: Executive Summary

  • Image Enhancament Overview
  • X-Ray and CT
  • Ultrasound
  • MRI
  • Radiopharmaceuticals
  • World Market Summary
  • Volume Growth
  • New Diagnostics
  • Toxicity Issues
  • Generic Competition
  • World Market Growth Analysis
  • Methodology

CHAPTER TWO: Introduction

  • Agents for the Early Detection of Disease
  • Two Functions
  • Adding Value
  • Key Clinical Markets
  • X-Ray and CT
  • Ultrasound
  • Updated Warning on Microbubbles
  • Microbubble Composition
  • Targeted and Untargeted
  • MRI
  • Novel Agents
  • Nuclear Medicine
  • Diagnosing Functionality
  • Sourcing Issues Updated
  • PET
  • New Applications
  • SPECT
  • Gamma Cameras
  • Risks
  • Ionic and Non-Ionic Contrast
  • Issues
  • Utilization Rate
  • Technical Challenges
  • Tracking Contrast Media
  • Contrast Modality Combinations
  • Emerging Applications
  • Atherosclerosis
  • Nanotechnology

CHAPTER THREE: Market Developments

  • Market Developments
  • FDA Approves Amyvid
  • Bayer HealthCare Business Integration
  • Bayer Receives Gadavist Approval
  • Agfa's Generic Push
  • Agfa's Generic Push
  • Improving Magnetic Resonance Visualization
  • Nanoparticle Contrast
  • Tracking Stem Cells

CHAPTER FOUR: Markets

  • Market Drivers
  • Withstanding the Recession
  • Combination Imaging and Disease Management
  • Opportunities from Increasing Specificity
  • Aging Population
  • Utilization
  • Procedures
  • Outlook for Contrast Media
  • Market Forecast
  • X-Ray and CT
  • Ultrasound
  • MRI
  • Outlook for Molecular Imaging Agents
  • Market Forecast

CHAPTER FIVE: Corporate Profiles

  • Acusphere Inc.
  • Alseres Pharmaceuticals, Inc.
  • Amag Pharmaceuticals Inc.
  • Aposense Ltd
  • ART Advanced Research Technologies Inc.
  • Avid Radiopharmaceuticals Inc.
  • Bayer HealthCare
  • Bracco SpA
  • Cardinal Health
  • Cell>Point
  • Covidien plc
  • Daiichi Pharmaceutucal Co., Ltd.
  • Draximage
  • Endocyte Inc.
  • Eusa Pharma
  • FluoroPharma Medical Inc.
  • GE Healthcare
  • Guerbet Group
  • Hovione Farmaciencia SA
  • Immunomedics Inc.
  • Insight Agents
  • Kereos Inc.
  • King Pharmaceuticals
  • Lantheus Medical Imaging
  • Luna Nanoworks
  • Macrocyclics
  • MDS Nordion
  • Molecular Insight Pharmaceuticals, Inc.
  • Nanoscan Imaginf LLC
  • Palatin Technologies Inc.
  • Pharmacyclics
  • Spago Imaging AB
  • Targeson Inc.
  • Taejoon Pharmaceutical Co., Ltd.
  • VisEn Medical
  • Zim Laboratories India Ltd.

List of Exhibits

CHAPTER ONE: Executive Summary

  • Exhibit 1: World Market for X-Ray Medical Contrast Media, 2011-2015
  • Exhibit 2: World Market for CT Medical Contrast Media, 2011-2015
  • Exhibit 3: World Market for Ultrasound Medical Contrast Media, 2011-2015
  • Exhibit 4: World Market for MRI Medical Contrast Media, 2011-2015
  • Exhibit 5: World Market for PET Radiopharmaceuticals, 2011-2015
  • Exhibit 6: World Market for SPECT Radiopharmaceuticals, 2011-2015

CHAPTER TWO: Introduction

  • Exhibit 7: Key Medical Contrast Agents by Type
  • Exhibit 8: Advantages of Non-Ionic Contrast Media Markets
  • Exhibit 9: Patent Status of Selected Medical Imaging Agents

CHAPTER FOUR: MARKETS

  • Exhibit 10: World Market for Medical Contrast Media and Radiopharmaceuticals, 2011-2015
  • Exhibit 11: World Market Share for Medical Contrast Media and Radiopharmaceuticals, 2011
  • Exhibit 12: World Market for Medical Contrast Media and Radiopharmaceuticals, 2015
  • Exhibit 13: Key Players' Percentage Share - Worldwide Medical Contrast Media Market, 2012
  • Exhibit 14: World Market Geographic Segmentation for Medical X-Ray Procedures, 2012
  • Exhibit 15: World Market Geographic Segmentation for Medical X-Ray Procedures, 2012
  • Exhibit 16: Worldwide Medical MRI Procedures, 2012
  • Exhibit 17: World Market Geographic Segmentation for Medical MRI Procedures, 2012
  • Exhibit 18: Worldwide Medical CT Procedures, 2012
  • Exhibit 19: World Market Geographic Segmentation for Medical CT Procedures, 2012
  • Exhibit 20: Worldwide Medical Ultrasound Procedures, 2012
  • Exhibit 21: World Market Geographic Segmentation for Medical Ultrasound Procedures, 2012
  • Exhibit 22: Worldwide Medical PET Procedures, 2012
  • Exhibit 23: World Market Geographic Segmentation for Medical PET Procedures, 2012
  • Exhibit 24: Worldwide Medical SPECT Procedures, 2012
  • Exhibit 25: World Market Geographic Segmentation for Medical SPECT Procedures, 2012
  • Exhibit 26: Status of Selected Medical Imaging Agents
  • Exhibit 27: World Markets for X-Ray Contrast Media, 2011-2015
  • Exhibit 28: World Market for Medical X-Ray Contrast Media by Geographic Segment, 2011-2015
  • Exhibit 29: World Market for Medical X-Ray Contrast Media by Geographic Segment, 2012
  • Exhibit 30: World Market for CT Contrast Media, 2011-2015
  • Exhibit 31: World Market for Medical CT Contrast Media by Geographic Segment, 2011-2015
  • Exhibit 32: World Market for Medical CT Contrast Media by Geographic Segment, 2012
  • Exhibit 33: World Market for Ultrasound Contrast Media, 2011-2015
  • Exhibit 34: World Market for Medical Ultrasound Contrast Media by Geographic Segment, 2011-2015
  • Exhibit 35: World Market for Medical Ultrasound Contrast Media by Geographic Segment, 2012
  • Exhibit 36: World Market for MRI Contrast Media by Geographic Segment, 2011-2015
  • Exhibit 37: World Market for Medical MRI Contrast Media by Geographic Segment, 2011-2015
  • Exhibit 38: World Market for Medical MRI Contrast Media by Geographic Segment, 2012
  • Exhibit 39: Selected Molecular Imaging Products
  • Exhibit 40: World Market for Medical PET Radiopharmaceuticals, 2011-2015
  • Exhibit 41: World Market for Medical PET Radiopharmaceuticals by Geographic Segment, 2011-2015
  • Exhibit 42: World Market for Medical PET Radiopharmaceuticals by Geographic Segment, 2012
  • Exhibit 43: World Market for Medical SPECT Radiopharmaceuticals, 2011-2015
  • Exhibit 44: World Market for Medical SPECT Radiopharmaceuticals by Geographic Segment, 2011-2015
  • Exhibit 45: World Market for Medical SPECT Radiopharmaceuticals by Geographic Segment, 2012
Show More
Pricing
Get Notified
Email me when related reports are published